Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.31
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell